The disease-based driving biology projects (DBP's) serve as the testbed of
i2b2. It is where we field, test and debug
the methodologies and tools developed in Cores 1 and 3. For this reason we
recognize that it is incumbent on us to use the DBP's to maximize interactions,
oversight and corrections in the directions of Core 1 and 3. Consequently for
each DBP, we have ensured the following:
- On each DBP there is an assigned computational/bioinformatics
co-investigator to ensure that there is a very close collaboration between
the clinical-genomic investigator and the methodologies and tools developed
in Cores 1 and 3. Also this computational co-investigator provides a
tighter loop for feedback and advice than would be ordinarily available.
- Frequent meetings between the clinical investigators of each DBP and the
methodologists from Core 1 and 3 (see Zak Kohane's blog for details).
- Data sharing for a twice a year showcasing of Cores 1 and Core 2 to the PI’s
and teams of the DBPs with formal feedback and requests for emphases
in particular veins of methodology or tool development.
Our DBPs have been selected with the following criteria:
- The diseases in question are of clinical significance.
- The PIs have particularly strong research track records.
- The proposed research plans are good models for future clinical research
using genomic technologies in combination with traditional clinical data
- The PIs evinced strong and enthusiastic willingness to work
together with computational researchers and engineers to help improve/further
their own research agenda.
- The degree to which the methods developed will be models for clinical research
of “complex diseases” in which a component of their phenotype
show familial aggregation, but no clear Mendelian segregation. This is not
to say that there will not be many productive clinical investigations of
largely monogenic disease for a long time to come and indeed one of our DBP’s
is placed foursquare on the transition from monogenic to complex diseases.
View current and past DBPs.